REG - IXICO plc - Result of AGM

IXICOAnnouncement

24/01/2025 14:30

For best results when printing this announcement, please click on link below:
https://newsfile.refinitiv.com/getnewsfile/v1/story?guid=urn:newsml:reuters.com:20250124:nRSX6671Ua&default-theme=true

RNS Number : 6671U  IXICO plc  24 January 2025

 

24 January 2025

IXICO plc

("IXICO" or the "Company")

 

Results of AGM

 

IXICO plc (AIM: IXI), the medical imaging advanced analytics company
delivering insights in neuroscience announces that all resolutions put forward
to its Annual General Meeting held earlier today were duly passed and the
votes cast were as follows:

 

     RESOLUTION                                                                    VOTES       %       VOTES     %      VOTES       % ISC VOTED  VOTES

FOR
AGAINST
TOTAL
WITHHELD
 1   Reports and Accounts                                                          68,485,623  99.95%  31,468    0.05%  68,517,091  73.94        400
 2a  Election of Bram Goorden                                                      68,473,140  99.95%  32,668    0.05%  68,505,808  73.93        11,683
 2b  Re-election of Grant Nash                                                     68,474,566  99.95%  36,376    0.05%  68,510,942  73.93        6,549
 2c  Re-election of Mark Warne                                                     68,473,966  99.95%  36,976    0.05%  68,510,942  73.93        6,549

 2d  Re-election of Dr Dipti Amin                                                  68,470,760  99.95%  35,048    0.05%  68,505,808  73.93        11,683
 2e  Re-election of Kate Rogers                                                    68,475,894  99.95%  35,048    0.05%  68,510,942  73.93        6,549
 3   Re-appointment of  Moore Kingston Smith Auditors                              68,473,359  99.95%  36,401    0.05%  68,509,760  73.93        7,731
 4   Allotment of Securities                                                       68,475,089  99.94%  41,502    0.06%  68,516,591  73.94        900
 5   * Disapply Pre-Emption Provisions                                             68,399,849  99.83%  116,742   0.17%  68,516,591  73.94        900
 6   * Issue of 'value multiple and exit' share options to Bram Goorden, CEO, and  68,352,128  99.76%  163,273   0.24%  68,515,401  73.94        2,090
     Grant Nash, CFO.
 7   * To adopt new Articles of Association for the Company                        68,473,361  99.94%  43,830    0.06%  68,517,191  73.94        300

* Special Resolutions

Please note that a 'vote withheld' is not a vote under English Law and is not
counted in the calculation

of the proportion of the votes 'for' and 'against' a resolution.

 

 

Further information:

 

 IXICO plc                                                                         +44 (0) 20 3763 7499
 Bram Goorden, Chief Executive Officer

 Grant Nash, Chief Financial Officer

 Cavendish Capital Markets Limited (Nominated Adviser and                          +44 (0) 20 7220 0500

 Sole Broker)
 Giles Balleny / Dan Hodkinson (Corporate Finance)

 Nigel Birks/Harriet Ward (Corporate Broking)

 Michael F Johnson / Tamar Cranford Smith (Sales)

 

About IXICO www.IXICO.com (http://www.IXICO.com)

IXICO is dedicated to delivering insights in neuroscience to help transform
the advancement of investigational therapies for neurological diseases, such
as Huntington's disease, Parkinson's disease and Alzheimer's disease. The
Company's purpose is to advance medicine and human health by turning data into
clinically meaningful information, providing valuable new insights in
neuroscience by supporting pharmaceutical companies across all phases of CNS
clinical research. IXICO's goal is to be a leading advocate of artificial
intelligence in medical image analysis.

IXICO has developed and deployed breakthrough data analytics, at scale,
through its remote access technology platform, to improve the return on
investment in drug development and reduce risk and uncertainty in clinical
trials for the Company's pharmaceutical clients.

 

This information is provided by RNS, the news service of the London Stock Exchange. RNS is approved by the Financial Conduct Authority to act as a Primary Information Provider in the United Kingdom. Terms and conditions relating to the use and distribution of this information may apply. For further information, please contact
rns@lseg.com (mailto:rns@lseg.com)
 or visit
www.rns.com (http://www.rns.com/)
.

RNS may use your IP address to confirm compliance with the terms and conditions, to analyse how you engage with the information contained in this communication, and to share such analysis on an anonymised basis with others as part of our commercial services. For further information about how RNS and the London Stock Exchange use the personal data you provide us, please see our
Privacy Policy (https://www.lseg.com/privacy-and-cookie-policy)
.   END  RAGPKQBDQBKDDDB